Baseline patient demographics for TETRIS, a prospective, non-interventional study to characterize the use of triple therapy for COPD in Germany

Rationale Although the GOLD report and national guidelines provide recommendations for initiation and maintenance of inhaled triple therapy (LAMA, LABA and ICS) in COPD, individual treatment decisions may differ. The TETRIS study follows patients on triple therapy, observing the rate of continuous treatment during the two-year study. TETRIS aims to elucidate influences on treatment decisions surrounding triple therapy in a real-world practice setting in Germany.

Methods TETRIS is a multi-centre, prospective observational study with two cohorts ( Cohort A: general practitioners and Cohort B : pulmonologists in private practice). Patients with COPD who have been treated with triple therapy for at least two but not longer than 48 weeks are enrolled and followed for 24 months.

The study will yield data in two parts:

1. Cross-sectional phenotyping of patients at study enrolment.

2. Longitudinal follow-up period to collect data (e.g., prescription, safety, spirometry) at three additional routine appointments.

Here, the data for part 1 are presented.

Results Baseline data were available for 1,213 patients with COPD recruited between January 2021 and June 2022. Key patient characteristics are shown in [Table 1].

Tab. 1

Tab. 1 Baseline characteristics.

Conclusions Baseline data reveal a symptomatic patient cohort, with the majority of patients being stepped up from dual to triple therapy. Data gathered over the next two years will provide more valuable insights into the patient journey and challenges associated with COPD treatment in Germany.

Funding GSK (214468)

Publication History

Article published online:
09 March 2023